Exclusive Summary

• • First in modality, clinically validated siRNA product with once-a-year dosing.
• • Global BIC LPA-siRNA with superior potency and durability at low dose.
• • Excellent LPA-siRNA data from Ph1 trial: >90% Lp(a) reduction sustained for 48 weeks in a single dose above 75 mg.
• • No traditional DDI concern with combination usage of small molecules.

Asset Materials

Contact Us for Full Materials